Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic outcomes of adjuvant chemotherapy in postoperative patients with cancer undergoing hemodialysis versus non-hemodialysis patients: a retrospective nationwide cohort study.

BMC cancer·2026
Same author

Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer.

Anticancer research·2026
Same author

Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges.

Cancer research communications·2026
Same author

Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303).

Japanese journal of clinical oncology·2026
Same author

Author Correction: Maintenance of R-loop structures by phosphorylated hTERT preserves genome integrity.

Nature cell biology·2026
Same author

Late-Onset Bilateral Malignant Ciliary Body Medulloepithelioma in an Adult.

Pathology international·2026

Related Experiment Video

Updated: Jun 4, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

[ALK inhibitor].

Hiroyuki Mano1

  • 1Division of Functional Genomics, Jichi Medical University, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2011
PubMed
Summary

Scientists discovered a new fusion tyrosine kinase, EML4-ALK, driving lung cancer. Targeting this kinase with ALK inhibitors showed promising results in eradicating lung cancer nodules in mice and is under investigation in human clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains the leading cause of cancer mortality globally.
  • The specific molecular drivers of lung cancer carcinogenesis are largely unidentified.
  • Genetic alterations, such as chromosomal inversions, can lead to novel oncogenic drivers.

Purpose of the Study:

  • To identify novel molecular mechanisms driving lung cancer.
  • To investigate the oncogenic potential of the EML4-ALK fusion tyrosine kinase.
  • To evaluate the therapeutic efficacy of ALK inhibitors in EML4-ALK-driven lung cancer.

Main Methods:

  • Discovery of the EML4-ALK fusion gene via analysis of chromosomal aberrations.
  • Generation of transgenic mouse models expressing EML4-ALK in lung tissue.

Related Experiment Videos

Last Updated: Jun 4, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

  • Treatment of EML4-ALK-expressing mice with a specific ALK inhibitor.

    • Main Results:

    • Identification of a novel fusion tyrosine kinase, EML4-ALK, resulting from a chromosome 2 inversion.
    • Transgenic mice expressing EML4-ALK rapidly developed numerous lung cancer nodules.
    • ALK inhibitor treatment effectively eradicated lung cancer nodules in EML4-ALK-expressing mice.

    Conclusions:

    • The EML4-ALK fusion kinase is a potent oncogenic driver of lung cancer.
    • Targeting EML4-ALK with ALK inhibitors represents a promising therapeutic strategy for lung cancer.
    • Ongoing clinical trials are evaluating the efficacy of ALK inhibitors in EML4-ALK-positive lung cancer patients.